复星医药(02196.HK)附属组合伙投资医疗器械诊断

阿斯达克财经
Yesterday

复星医药(02196.HK) 公布,附属复星平耀与上海复健、控股股东复星高科技及复曜智港签订合伙协议,拟共同设立河南复健,分别以现金出资490万、10万、290万、210万元人民币,权益占比分别为49%、1%、29%、21%。
复星医药指,为加强大健康产业的布局,拟参与发起设立以中原地区为中心,以医疗器械诊断、生命科学、创新药及其上下游产业链为主要投资方向的股权投资基金。河南复健设立后,拟作为发起设立该股权投资基金的普通合伙人。(ha/a)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-25 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10